Abzena plc has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S. to equip its integrated CDMO facilities in Bristol, PA, which provides development and GMP manufacture of antibody drug conjugates, and San Diego, CA, which provides development and GMP manufacture of monoclonal antibodies and other recombinant proteins.
 
Sartorius Stedim will provide both facilities with process solutions in single-use (SU) format. It will equip Abzena’s San Diego process development lab with technologies such as Ambr250, enabling scale up to 500L initially and later to the 2000L scale single-use bioreactor for its center of excellence in clinical manufacturing.
 
John Burt, Abzena chief executive officer, said, “In addition to having selected Sartorius’ industry leading single-use technologies for antibody and ADC production, the Abzena facilities will feature Umetrics process analytics software throughout the process ensuring that all the data captured throughout our clients’ molecule development is transformed into process knowledge ensuring that we can rapidly develop a robust and reliable process that can be easily scaled up to ensure a smooth technology transfer.”
 
Reinhard Vogt, Sartorius executive vice president said, “We are pleased to have been selected by Abzena, a prominent global CDMO with a comprehensive industry portfolio across a wide range of modalities to supply single-use solutions that enable process development, tech transfer and GMP manufacturing. We look forward to working together to best serve the US and international markets.”